Blueprint Medicines Corporation (2L9.F)
- PR Newswire
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced multiple upcoming datasets across two key conferences that reinforce the significant real-world burden of systemic mastocytosis (SM), and highlight the durable clinical outcomes of AYVAKIT®/AYVAKYT® (avapritinib) across the spectrum of the disease. The presentations, which build on over a decade of pioneering research with clinical experts and patient advocates, will be reported at the following meetings:
- PR Newswire
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced updated data from the ongoing Phase 1 dose escalation portion of the VELA clinical trial of BLU-222, an investigational, highly selective and potent CDK2 inhibitor, in combination with ribociclib and fulvestrant in patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. The data, which mark the first promising clinical results for a CDK2 inhibitor in combination with an app
- Simply Wall St.
Blueprint Medicines (NASDAQ:BPMC) pulls back 3.5% this week, but still delivers shareholders notable 85% return over 1 year
If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost...
